Document:

Form of Stock Option Grant Letter to Non-Employee Directors

 Exhibit 10.2 
  

	Re:	Board of Directors Stock Option Grant 

 Dear
                                        ,

 Upon the recommendation of the Governance and Compensation Committee of the Board of Directors of Airgas, Inc., and the
approval of the Board of Directors, pursuant to the Airgas, Inc. Amended and Restated 2006 Equity Incentive Plan (the “Plan”), effective August ##, 20## (the “Grant Date”) you are hereby granted a non-qualified stock option (the
“Option”) to purchase #,#00 shares of common stock, at $##.## per share. 
 This Option is subject to the applicable
terms and conditions of the Plan which are incorporated herein by reference, and in the event of any contradiction, distinction or differences between this letter and the terms of the Plan, the terms of the Plan will control. The Plan was sent to
you earlier together with the prospectus for the Plan. We are not sending the latest annual report and proxy statement with this letter as you have received them due to your ownership of Airgas common shares or you hold other Airgas stock options.
You will be sent a new Annual Report and Proxy Statement each year as they become available to Airgas shareholders. 
 The
Option granted herein shall be exercisable in full on the Grant Date and shall terminate in full at 5:00 P.M. local Philadelphia, Pennsylvania time on August ##, 20##, unless sooner terminated as specified in Section 6.7 of the Plan.

 In order to excise your vested options, you should contact Merrill Lynch to review your account. For
information about your account and to exercise options, call Merrill Lynch at
        -        -         to speak to
                             or another Participant Service Representative or visit the web site at
www.benefits.ml.com. 
 If you need any further clarification, please don’t hesitate to call me at
        -        -        . 
 Sincerely,Waiver of Rights Upon Issuance of Other Securities dated July 29, 2009

 Exhibit 4.3 
 ANTIGENICS, INC. 
 Waiver of Rights Upon Issuance of Other
Securities 
 RECITALS 
  

	1.	Reference is made to the Senior Secured Convertible Notes issued on October 30, 2006 (together with any senior secured convertible notes issued in replacement or
exchange thereof in accordance with the terms thereof and any senior secured convertible notes issued to pay interest, the “Notes”), by Antigenics, Inc., a Delaware corporation (the “Company”) to Ingalls &
Snyder Value Partners L.P. (“Ingalls”) and Penrith LTD (“Penrith” and together with Ingalls, the “Investors”). 

  

	2.	Pursuant to an Agreement to be negotiated and executed within 30 days of the date hereof to be entered into between the Company and certain prospective investors, the
Company will agree to sell and issue up to an aggregate number of shares equal to $20,000,000 shares of Common Stock of the Company, par value $0.01 per share (“Common Shares”), and warrants (“Warrants”) to purchase
up to an additional $10,000,000 shares of Common Stock (the Common Shares, Warrants and the Common Stock issuable upon exercise of the Warrants, “New Securities”). 

  

	3.	Pursuant to Section 7(a) of the Notes, the Investors will have certain anti-dilutive rights upon issuance of the New Securities proposed to be sold and issued (the
“Anti-Dilutive Rights”). 

  

	4.	The undersigned parties desire to permit the sale and issuance of the New Securities without triggering the Anti-Dilutive Rights. 

  

	5.	The undersigned Ingalls holds 2006 Notes representing at least a majority of the aggregate principal amount of the 2006 Notes outstanding as of the date hereof.

 NOW THEREFORE, the undersigned agree as follows: 
  

	1.	Waiver. The Investors hereby waive all of their rights under Sections 4 and 7(a) of the Notes with respect to the sale, issuance and exercise of the New
Securities. 

  

	2.	Miscellaneous. Other than as specifically set forth herein, this Consent of Rights Upon Issuance of Other Securities shall not be construed as a consent to any
future action or a waiver of any right or remedy on any future occasion. This Waiver of Rights Upon Issuance of Other Securities may be executed in one or more counterparts, all of which shall be considered one and the same waiver.

 [Signature Page Follows] 

 IN WITNESS WHEREOF, the undersigned have executed this Waiver of Rights Upon Issuance of
Other Securities as of July 31, 2009. 
  

					
	 ANTIGENICS INC.

		
	 By:
	 	 /s/ Shalini Sharp

		 	 Name:
	 	Shalini Sharp
		 	 Title:
	 	CFO

  

			
	 INVESTORS:

	
	 INGALLS & SNYDER VALUE PARTNERS L.P.

		
	 By:
	 	 /s/ Thomas O. Boucher Jr.

	 Name:
	 	Thomas O. Boucher Jr. 
	 Title:
	 	General PartnerWaiver of Rights Upon Issuance of Other Securities dated August 3, 2009

 Exhibit 4.6 
 ANTIGENICS INC. 
 Waiver of Rights Upon Issuance of Other
Securities 
 RECITALS 
  

	1.	Reference is made to the Senior Secured Convertible Notes issued on October 30, 2006 (together with any senior secured convertible notes issued in replacement or
exchange thereof in accordance with the terms thereof and any senior secured convertible notes issued to pay interest, the “Notes”), by Antigenics, Inc., a Delaware corporation (the “Company”) to Ingalls &
Snyder Value Partners L.P. (“Ingalls”) and Penrith LTD (“Perinth” and together with Ingalls, the “Investors”). 

  

	2.	Pursuant to an Agreement to be negotiated and executed within 30 days of the date hereof to be entered into between the Company and certain prospective investors, the
Company will agree to sell and issue common shares, par value $0.01 per share, (“Common Shares”) in exchange for up to $12,000,000 in gross proceeds, and warrants (“Warrants”) to purchase up to the same number of
additional shares of Common Stock (the Common Shares, Warrants and the Common Stock issuable upon exercise of the Warrants, “New Securities”). 

  

	3.	Pursuant to Section 7(a) of the Notes, the Investors will have certain anti-dilutive rights upon issuance of the New Securities proposed to be sold and issued (the
“Anti-Dilutive Rights”). 

  

	4.	The undersigned parties desire to permit the sale and issuance of the New Securities without triggering the Anti-Dilutive Rights and adjust the Fixed Conversion Price
(as defined in the Notes) from $3.50 to $3.00. 

  

	5.	The undersigned Ingalls holds 2006 Notes representing at least a majority of the aggregate principal amount of the 2006 Notes outstanding as of the date hereof.

 NOW THEREFORE, the undersigned agree as follows: 
  

	1.	Waiver. The Investors hereby waive all of their rights under Sections 4 and 7(a) of the Notes with respect to the sale, issuance and exercise of the New
Securities. 

  

	2.	Amendment. The Company and the Investors hereby agree to amend Section 2(b)(ii) of the Notes such that Section 2(b)(ii) shall read as follows:

 “Fixed Conversion Price” means $3.00 (also referred to as the “Initial Fixed Conversion
Price”), subject to adjustment as provided herein. 
  

	3.	 Miscellaneous. Other than as specifically set forth herein, this Consent of Rights Upon Issuance of Other Securities shall not be construed as a
consent to any future

	 	 
action or a waiver of any right or remedy on any future occasion. This Waiver of Rights Upon Issuance of Other Securities may be executed in one or more counterparts, all of which shall be
considered one and the same waiver. 

 [Signature Page Follows] 

 IN WITNESS WHEREOF, the undersigned have executed this Waiver of Rights Upon Issuance of
Other Securities as of August 3, 2009. 
  

					
	 ANTIGENICS INC.

		
	 By:
	 	 /s/ Shalini Sharp

		 	 Name:
	 	Shalini Sharp
		 	 Title:
	 	CFO

  

			
	INVESTORS:
	
	 INGALLS & SNYDER VALUE PARTNERS L.P.

		
	 By:
	 	 /s/ Thomas O. Boucher Jr.

	 Name:
	 	Thomas O. Boucher Jr. 
	 Title:
	 	General PartnerFirst Amendment to Employment Agreement dated July 2, 2009 for Garo Armen

 Exhibit 10.1 
 Confidential 
 AMENDMENT – NUMBER ONE

 AGREEMENT 
 This Amendment Number One (this “Amendment 1”) is effective as of July 2, 2009 by and between Antigenics Inc., a Delaware corporation, having its principle place of business at 3 Forbes
Road, Lexington, Massachusetts 02421, USA (the “Company”) and Garo Armen (the “Executive”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement (defined below). 
 WITNESSETH 
 WHEREAS, the parties have entered into an Agreement effective as December 1, 2005 setting forth employment terms (the “Agreement”); and 
 WHEREAS, the parties now wish to amend the Agreement to reflect certain changes in the Company’s Executive Change in Control Plan as set forth herein; 
 NOW, THEREFORE, the parties agree as follows: 
  

	 	1.	Section 5(g)(i) of the Agreement is hereby deleted in its entirety and replaced with the following: 

 (i) if a Change of Control occurs on the date of such Change in Control, fifty-percent (50%) of any
(A) outstanding unvested stock options or (B) shares of unvested restricted stock of the Company, granted or issued to the Executive as of the date of the Change in Control shall become vested, exercisable and, in the case of shares of
restricted stock, no longer subject to forfeiture, provided that the Executive is employed by the Company on the date of such Change in Control. 
  

	 	2.	Section 5(g)(ii) of the Agreement is hereby deleted in its entirety and replaced with the following: 

 (ii) if a Change of Control occurs and within twenty-four (24) months following such Change of Control, the Company
terminates the Executive’s employment other than for Cause, or the Executive terminates his employment for Good Reason, then, in lieu of any payments to or on behalf of the Executive under Section 5.d or 5.e hereof, the Company shall pay
to the Executive in one lump sum an amount equal to (A) twenty-four (24) months Base Salary at the rate in effect on the date of termination. plus (B) two times the higher of (x) the Executive’s target incentive bonus under
the Executive Incentive Plan for the year in which the Executive’s employment is terminated or (y) the actual incentive bonus paid to the Executive, if any, under the Executive Incentive Plan for the last full fiscal year preceding the
year in which the Executive’s employment is terminated; and shall also, until the conclusion of a period of twenty-four

 
(24) months following the date of termination, pay the full premium cost of the Executive’s participation in the Company’s group medical and dental insurance plans, provided that the
Executive is entitled to continue such participation under applicable law and plan terms. In addition, any (I) outstanding unvested stock options granted or issued to the Executive as of the date of the Change in Control shall become vested and
shall be exercisable for ninety (90) days following termination of the Executive’s employment and (II) shares of unvested restricted stock of the Company granted or issued to the Executive as of the date of the Change in Control shall
become vested and no longer subject to forfeiture. The Company will also provide the Executive with an outplacement assistance benefit in the form of a lump-sum payment of $15,000 plus an additional lump-sum payment in an amount sufficient, after
giving effect to all federal, state and other taxes with respect to such additional payment, to make Executive whole for all taxes (including withholding taxes) on such outplacement assistance benefit. For the purpose of this Section 5.g alone,
in addition to the definition provided in Section 5.e, Good Reason shall also mean the relocation of the Executive’s principal office, without his prior consent, to a location more than thirty (30) miles from its location on the day
prior to the Change in Control. 
  

	 	3.	Section 6(a) of the Agreement is hereby deleted in its entirety and replaced with the following: 

 (a) Payment(s) by the Company and contributions to the cost of the Executive’s continued participation in the
Company’s group health and dental plans that may be due the Executive in each case under the applicable termination provision of Section 5 shall constitute the entire obligation of the Company to the Executive. In order to receive any
payments, benefits continuation, accelerated vesting of stock options or shares of restricted stock or any other benefits under Section 5.d or 5.e or 5.g or 5.h, the Executive must first execute a General Release of Claims in a form acceptable
to the Company. 
  

	 	4.	The parties acknowledge and agree that, except as set forth in this Amendment 1, the Agreement shall remain in full force and effect. 

  

	 	5.	This Amendment 1 shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, U.S.A. irrespective of any conflicts of law
principles thereof. 

  

	 	6.	This Amendment 1 may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such
counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of the parties hereto. 

 [SIGNATURE PAGE FOLLOWS] 
  

 2 

 Confidential 
 IN WITNESS WHEREOF, the parties each have caused this Amendment 1 to be executed by their respective duly authorized representative as of
the date first set forth above. 
  

			
	 ANTIGENICS INC., a Delaware corporation

		
	 By:
	 	 /s/ Wadih Jordan

	 Name:
	 	Wadih Jordan
	 Title:
	 	Director
	
	 Executive

		
	 By:
	 	 /s/ Garo Armen

	 Name:
	 	Garo Armen

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]